ADC Toxin Molecule Composition for Targeted Tumor Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in achieving high efficacy against tumor cells while minimizing toxicity to normal cells, with a need for more effective cytotoxic agents like camptothecin derivatives.
Innovation Solution
A novel toxin molecule, represented by specific compounds of formula (I) or their pharmaceutically acceptable salts, is developed to enhance tumor cell proliferation inhibition in ADCs, offering improved specificity and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If traditional chemotherapy drugs are used, then tumor cell proliferation is inhibited, but normal cells are also affected causing excessive toxic side effects
Solution Approach 1:
The drug is segmented into two functional parts: a targeting component (antibody or antibody fragment) that selectively binds to tumor cells, and a cytotoxic component that kills the tumor cells. This segmentation allows the toxic effect to be confined only to tumor cells that express the target antigen, thereby reducing toxic side effects on normal cells while maintaining efficacy against tumor cells.
Solution Approach 2:
An intermediary linker molecule is used to connect the antibody component to the cytotoxic component. This intermediary serves as a carrier that delivers the cytotoxic agent specifically to tumor cells through the antibody's binding activity, enabling the toxic effect to be exerted only on the target cells and minimizing harm to normal cells.
2Measurement precision
If antibody-drug conjugates are designed to target specific antigens, then specificity against normal cells is improved, but the complexity of the conjugate structure increases
Solution Approach 1:
The conjugate is divided into distinct functional modules: the antibody component for targeting, the linker for connection, and the cytotoxic component for killing. This modular segmentation allows each component to be optimized independently for its specific function while maintaining overall specificity, managing the structural complexity through functional decomposition.
Solution Approach 2:
The linker molecule's parameters (such as length, chemical structure, and stability) are carefully selected and optimized to balance the conjugate's stability in circulation with its ability to deliver the cytotoxic agent to the target. By adjusting these parameters, the conjugate achieves high specificity without excessive structural complexity.
3Reliability
If camptothecin derivatives are used as cytotoxic agents, then anti-tumor effects are achieved by inhibiting topoisomerase I, but the need for developing more effective ADC drugs remains
Solution Approach 1:
The cytotoxic component's parameters (such as chemical structure, molecular weight, and binding affinity to topoisomerase I) are optimized to enhance anti-tumor efficacy. By adjusting these parameters, the conjugate achieves stronger inhibition of topoisomerase I while maintaining compatibility with the antibody-linker system, thereby developing more effective ADC drugs.
Solution Approach 2:
The ADC combines multiple functional components (antibody, linker, and optimized cytotoxic agent) into a composite molecular structure. This composite approach allows the synergistic interaction of different components to achieve enhanced anti-tumor effects that exceed the sum of individual parts, driving the development of more effective ADC therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel toxin molecule effectively inhibits tumor cell proliferation with enhanced specificity and reduced toxicity to normal cells, providing a more effective treatment for various cancers.
Implementation Method 1
Camptothecin and its analogs terminate progressive unwinding by reversibly binding to the DNA topoisomerase I-DNA complex, forming a ternary complex of camptothecin and its analogs-DNA topoisomerase I-DNA, which ultimately makes the replication forks crash into the ternary complex and induces unrepairable DNA breaks
Implementation Method 2
forming a ternary complex of camptothecin and its analogs-DNA topoisomerase I-DNA
Data Source
AI summary
The present application provides a toxin molecule suitable for an antibody-drug conjugate. In particular, the present application provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt or hydrate thereof. The compound of the present application can be used in the preparation of a pharmaceutical composition for treating diseases associated with tumor cell proliferation.